Alvotech and Teva get US FDA approval of Selarsdi

SELARSDI is approved for both adult and pediatric indications and is the second biosimilar approved under the strategic partnership between Alvotech and Teva

Positive data for Roche multiple sclerosis injection

US FDA and EMA accepted filings based on the data from OCARINA II, with EU approval anticipated mid-2024 and U.S. approval anticipated September 2024

Moderna pauses plan to build mRNA manufacturing facility in Kenya

The demand in Africa for COVID-19 vaccines has declined

Novartis reports data from trial of IgA nephropathy treatment

IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide

Novartis tender offer for MorphoSys commences

The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months

Granules India’s Unit V facility in Visakhapatnam completes USFDA inspection with zero 483 observations

This facility manufactures APIs & formulations of oncology and non-oncology products.

USFDA completes inspection of Lupin's Dabhasa facility with no observations

The inspection was conducted from April 8 to April 12, 2024 and concluded with no observations

Generics gain ground, yet HCPs still favor branded drugs, finds GlobalData

A significant proportion of healthcare professionals still tend to favor branded drugs

Piramal Pharma forays into men's grooming market in India with the launch of BOHEM

Evonik launches Botanicals & Natural Actives business segment

Aims to become a leading global partner for botanical extracts and natural actives in the beauty and personal care market